-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Eterna Therapeutics (NASDAQ:ERNA) Shares Down 7.3%
Eterna Therapeutics (NASDAQ:ERNA) Shares Down 7.3%
Shares of Eterna Therapeutics Inc. (NASDAQ:ERNA – Get Rating) traded down 7.3% during trading on Tuesday . The company traded as low as $3.03 and last traded at $3.18. 13,899 shares traded hands during mid-day trading, a decline of 74% from the average session volume of 54,272 shares. The stock had previously closed at $3.43.
Eterna Therapeutics Stock Performance
The stock has a 50 day moving average of $3.55.
Get Eterna Therapeutics alerts:Insiders Place Their Bets
In related news, Director Nicholas Jason Singer purchased 283,286 shares of the business's stock in a transaction on Friday, December 2nd. The stock was acquired at an average price of $3.28 per share, with a total value of $929,178.08. Following the purchase, the director now directly owns 266,214 shares in the company, valued at $873,181.92. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Eterna Therapeutics news, major shareholder John D. Halpern acquired 335,920 shares of the business's stock in a transaction dated Friday, December 2nd. The stock was bought at an average price of $3.28 per share, with a total value of $1,101,817.60. Following the purchase, the insider now owns 450,961 shares of the company's stock, valued at $1,479,152.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Nicholas Jason Singer acquired 283,286 shares of the business's stock in a transaction dated Friday, December 2nd. The stock was acquired at an average cost of $3.28 per share, with a total value of $929,178.08. Following the purchase, the director now directly owns 266,214 shares in the company, valued at approximately $873,181.92. The disclosure for this purchase can be found here. Corporate insiders own 20.50% of the company's stock.
About Eterna Therapeutics
(Get Rating)Brooklyn ImmunoTherapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease.
See Also
- Get a free copy of the StockNews.com research report on Eterna Therapeutics (ERNA)
- 3 Industrial Stocks to Help Build Your 2023 Watchlist
- The Institutions Choose CarMax Over Carvana, Should You?
- Heatmap in Trading: How to Learn What Market Depth Hides
- Micron Technology Sees Chip Recovery by the End of 2023
- Three Healthcare Penny Stocks to Watch In The New Year
Receive News & Ratings for Eterna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eterna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Eterna Therapeutics Inc. (NASDAQ:ERNA – Get Rating) traded down 7.3% during trading on Tuesday . The company traded as low as $3.03 and last traded at $3.18. 13,899 shares traded hands during mid-day trading, a decline of 74% from the average session volume of 54,272 shares. The stock had previously closed at $3.43.
埃特纳治疗公司(纳斯达克代码:ERNA-GET评级)的股票在周二的交易中下跌了7.3%。该公司股价低至3.03美元,最新报3.18美元。午盘成交量为13,899股,较54,272股的平均成交量下降74%。该股此前收盘价为3.43美元。
Eterna Therapeutics Stock Performance
Eterna Treateutics股票表现
The stock has a 50 day moving average of $3.55.
该股的50日移动均线为3.55美元。
Insiders Place Their Bets
内部人士下注
In related news, Director Nicholas Jason Singer purchased 283,286 shares of the business's stock in a transaction on Friday, December 2nd. The stock was acquired at an average price of $3.28 per share, with a total value of $929,178.08. Following the purchase, the director now directly owns 266,214 shares in the company, valued at $873,181.92. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Eterna Therapeutics news, major shareholder John D. Halpern acquired 335,920 shares of the business's stock in a transaction dated Friday, December 2nd. The stock was bought at an average price of $3.28 per share, with a total value of $1,101,817.60. Following the purchase, the insider now owns 450,961 shares of the company's stock, valued at $1,479,152.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Nicholas Jason Singer acquired 283,286 shares of the business's stock in a transaction dated Friday, December 2nd. The stock was acquired at an average cost of $3.28 per share, with a total value of $929,178.08. Following the purchase, the director now directly owns 266,214 shares in the company, valued at approximately $873,181.92. The disclosure for this purchase can be found here. Corporate insiders own 20.50% of the company's stock.
在相关新闻中,董事尼古拉斯·贾森·辛格在12月2日(星期五)的一次交易中购买了283,286股该公司的股票。该股是以每股3.28美元的平均价格收购的,总价值为929,178.08美元。收购完成后,董事现在直接拥有该公司266,214股,价值873,181.92美元。此次收购是在提交给美国证券交易委员会的一份文件中披露的,该文件可以通过此超链接。在Eterna Treeutics的其他消息中,大股东John D.Halpern在12月2日星期五的交易中收购了该公司股票的335,920股。这只股票是以每股3.28美元的平均价格购买的,总价值为1101,817.60美元。收购完成后,这位内部人士现在拥有450,961股该公司股票,价值1,479,152.08美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可在此超链接。此外,在12月2日星期五的一笔交易中,董事尼古拉斯·贾森·辛格购买了283,286股该公司的股票。这只股票是以每股3.28美元的平均成本收购的,总价值为929,178.08美元。收购完成后,董事现在直接拥有该公司266,214股,价值约873,181.92美元。关于这次购买的披露可以找到这里。公司内部人士持有该公司20.50%的股份。
About Eterna Therapeutics
关于Eterna治疗公司
Brooklyn ImmunoTherapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease.
布鲁克林免疫疗法公司是一家临床阶段的生物制药公司,致力于开发治疗癌症患者的疗法。它的先进计划是IRX-2,这是在头颈部鳞状细胞癌患者的2b期临床试验中。该公司还开发使用基因编辑和细胞治疗技术的疗法,用于治疗肿瘤学、血液疾病和单基因疾病。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Eterna Therapeutics (ERNA)
- 3 Industrial Stocks to Help Build Your 2023 Watchlist
- The Institutions Choose CarMax Over Carvana, Should You?
- Heatmap in Trading: How to Learn What Market Depth Hides
- Micron Technology Sees Chip Recovery by the End of 2023
- Three Healthcare Penny Stocks to Watch In The New Year
- 免费获取StockNews.com关于Eterna治疗的研究报告(Erna)
- 帮助你建立2023年观察名单的3只工业股票
- 这些机构选择CarMax而不是Carvana,你应该这样做吗?
- 交易热图:如何了解隐藏的市场深度
- 美光科技预计2023年底芯片回收
- 新年值得关注的三只医疗保健便士股
Receive News & Ratings for Eterna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eterna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Eterna治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Eterna Treeutics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧